IL6 and COVID-19: Previous clinical study already demonstrated that losmapimod (p38 inhibitor) is involved in the reduction of pro-inflammatory biomarkers such as CRP and IL-6; therefore, the FDA approved phase III clinical study of losmapimod as a potential treatment for COVID-19 (LOSVID clinical trial).